key: cord-0804115-jhxmxa02
authors: van der Lubbe, Joan E.M.; Rosendahl Huber, Sietske K.; Vijayan, Aneesh; Dekking, Liesbeth; van Huizen, Ella; Vreugdenhil, Jessica; Choi, Ying; Baert, Miranda R.M.; Feddes-de Boer, Karin; Gil, Ana Izquierdo; van Heerden, Marjolein; Dalebout, Tim J.; Myeni, Sebenzile K.; Kikkert, Marjolein; Snijder, Eric J.; de Waal, Leon; Stittelaar, Koert J.; Tolboom, Jeroen T.B.M.; Serroyen, Jan; Muchene, Leacky; van der Fits, Leslie; Rutten, Lucy; Langedijk, Johannes P.M.; Barouch, Dan H.; Schuitemaker, Hanneke; Zahn, Roland C.; Wegmann, Frank
title: Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing
date: 2021-01-08
journal: bioRxiv
DOI: 10.1101/2021.01.08.425915
sha: 9d0aa00516b88e3dac16f7ee9526ca33fae51c5f
doc_id: 804115
cord_uid: jhxmxa02

Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster and non-human primate SARS-CoV-2 infection models. Here, we investigated the immunogenicity, protective efficacy and potential for vaccine-associated enhanced respiratory disease (VAERD) mediated by Ad26.COV2.S in a moderate disease Syrian hamster challenge model, using the currently most prevalent G614 spike SARS-CoV-2 variant. Vaccine doses of 1×109 vp and 1×1010 vp elicited substantial neutralizing antibodies titers and completely protected over 80% of SARS-CoV-2 inoculated Syrian hamsters from lung infection and pneumonia but not upper respiratory tract infection. A second vaccine dose further increased neutralizing antibody titers which was associated with decreased infectious viral load in the upper respiratory tract after SARS-CoV-2 challenge. Suboptimal non-protective immune responses elicited by low-dose A26.COV2.S vaccination did not exacerbate respiratory disease in SARS-CoV-2-inoculated Syrian hamsters with breakthrough infection. In addition, dosing down the vaccine allowed to establish that binding and neutralizing antibody titers correlate with lower respiratory tract protection probability. Overall, these pre-clinical data confirm efficacy of a 1-dose vaccine regimen with Ad26.COV2.S in this G614 spike SARS-CoV-2 virus variant Syrian hamster model, show the added benefit of a second vaccine dose, and demonstrate that there are no signs of VAERD under conditions of suboptimal immunity.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent of 46 coronavirus disease 2019 (COVID-19), is responsible for an unprecedented crisis in the world 1 . 47

While physical measures such as social distancing and deployment of face masks are being 48 employed to reduce the spread of the virus, safe and effective vaccines are crucial to contain this 49 pandemic. 50 We recently demonstrated that a single dose of adenovirus serotype 26 (Ad26) vaccine expressing 51 a pre-fusion stabilized spike antigen (Ad26.CoV2.S) is immunogenic in animals and humans 2-5 52 and protected rhesus macaques against challenge with SARS-CoV-2 2 . Protection correlated with 53 SARS-CoV-2 binding and neutralizing antibodies, in agreement with findings with other COVID-54 19 vaccine candidates [6] [7] [8] . 55 We have also demonstrated vaccine mediated protection against SARS-CoV-2 challenge in Syrian 56 hamsters. In this animal model, SARS-CoV-2 infection is characterized by severe clinical disease 57 including body weight loss and respiratory tract histopathology upon high-dose intranasal 58 challenge 3,9-11 , mimicking findings in humans where viral inoculum size has been correlated with 59 disease severity [12] [13] [14] [15] . In those studies, challenge in Syrian hamsters was performed with SARS-60

CoV-2 USA-WA1/2020 which has a 100% homologous spike sequence to the Ad26.COV2.S 61 vaccine antigen 3,4 . Since then, SARS-CoV-2 variants with a D614G spike substitution have 62 become most prevalent 16,17 , albeit recently new strains with additional mutations in spike further 63 distant from the original Wuhan strain are emerging and became more widespread [18] [19] [20] . In Syrian 64 hamsters, comparison of a SARS-CoV-2 strain with and without the D614G substitution in the 65 spike protein indicated that the G614 variant produced higher infectious viral titers in the upper 66 respiratory tract and increases competitive fitness 21, 22 . 67 5 A potential concern of coronavirus vaccines is that they may predispose for disease enhancement 68 after breakthrough infection, by eliciting only low-or non-neutralizing antibodies in combination 69 with a Th2 skewed cellular response 14,23-25 . Vaccine-associated enhanced respiratory disease 70 (VAERD) has been described for vaccine candidates for SARS-CoV and MERS-CoV but only in 71 some animal models [26] [27] [28] [29] [30] week 8 for the 2-dose regimen in Syrian hamsters. At 4 days post inoculation (dpi), animals were 159 sacrificed, and lungs, nasal turbinates and throat swabs were analyzed for viral load and 160 pathological changes. To increase the power of the statistical analysis and since we did not observe 161 a pronounced dose responsiveness for the virology readouts, we pooled viral load readouts for 162 comparison to the Ad26.Empty control group. Comparisons between the three different vaccines 163 (Ad26.COV2S, Ad26.S, Ad26.dTM.PP) were conducted across dose levels. 164

After a single vaccination and subsequent challenge, median lung viral load in all vaccine groups 165 was significantly lower compared with the Ad26.Empty control group (median viral load 10 7.3 166 TCID50/g) ( Fig 3A) . Virus was detected in the lungs of 11 out of 12 animals immunized with a 167 single dose of Ad26.S (median viral load 10 9 VP 10 5.6 TCID50/g, 10 10 VP 10 5 TCID50/g), and in 168 10 out of 12 animals immunized with a single dose of A26.dTM.PP (median viral load 10 9 VP 169 10 5.3 TCID50/g, 10 10 VP 10 5.7 TCID50/g) and no clear effect of vaccine dose was observed. By 170 contrast, only 3 out of 12 animals immunized with a single dose of Ad26.COV2.S had detectable 171 virus in the lung (median viral load of 10 9 VP and 10 10 VP 10 1.2 TCID50/g). Of hamsters vaccinated 172 with a second dose of Ad26.COV2.S, again 3 out of 12 animals had detectable viral load for both 173 vaccine dose levels, suggesting no added value of the second dose. Viral load in the animals with 174 breakthrough infections were also similar to the viral load in animals with breakthrough infections 175 after one vaccination. A second dose of 10 9 VP Ad26.S or Ad26.dTM.PP also had little impact on 176 the lung infection rate post challenge at week 8 (5 out of 6 animals showed detectable viral load 177 per vaccine, median titer 10 4.9 TCID50/g and 10 6.7 TCID50/g, respectively ) but a second dose of 178 10 10 VP of these prototype vaccines was associated with a lower lung infection rate and median 179 lung viral loads compared with the 1-dose regimens (median titer 10 2 TCID50/g and 10 4 TCID50/g, 180 respectively), suggesting a benefit of a 2 dose regimen ( Fig 3B) . 181

To determine the impact of the vaccines on viral load in the upper respiratory tract, nasal turbinate 182 viral load was determined after sacrifice at 4 dpi, and throat swab viral load was determined daily 183 after infection and was analyzed as area under the curve (AUC) per animal up to day 4 post 184 infection. In animals receiving a single vaccine dose, a limited but statistically significant reduction 185 in nasal turbinate viral load after challenge was observed for Ad26.dTM.PP but not for 186

Ad26.COV2.S and Ad26.S compared with the control group. After 2 vaccine doses, all three 187 vaccines induced a significant reduction in nasal turbinate viral load post challenge compared with 188 the Ad26.Empty group (Fig 3C and D) . By contrast, throat swab viral load data show that none of 189 the vaccines reduced viral burden in the throat after single immunization and subsequent 190 inoculation with SARS-CoV-2 (Fig 3E) , and only animals immunized with two doses 191

Ad26.COV2.S had significantly reduced throat viral load compared to control (Fig 3F) . 192

The observed protective efficacy results are further supported by immunohistochemistry (IHC) 193 staining for SARS-CoV-2 NP in the lung and nose tissue, and by histopathology ( Supp Fig 4 and Groups of hamsters were immunized with a single dose of Ad26.COV2.S at 10 7 , 10 8 , 10 9 or 10 10 205 VP (4 groups; n=8/group). The control group received 10 10 VP of a control vaccine encoding an 206 irrelevant antigen (Ad26.Irr). At 4 weeks post immunization we observed a clear dose response of 207 binding and neutralizing antibodies, both in number of responding animals and in antibody titers, 208 with no detectable binding or neutralizing antibody titers in 1 or 3 out of 8 animals at the lowest 209 dose level of 10 7 VP (Fig 4A and B) , respectively. For the 10 9 and 10 10 VP doses, median levels 210 of binding antibodies (median endpoint titer of 10 3.7 and 10 3.9 , respectively) and median 211 neutralizing antibody responses (median neutralization titers of 45 and 91, respectively) were 212 consistent with observations in the previous study. Four weeks after immunization, hamsters were 213 inoculated with 10 2 TCID50 SARS-CoV-2 followed by determination of efficacy and 214 histopathology readouts as in the previous study. Animals dosed with 10 9 and 10 10 VP of 215

Ad26.COV2.S showed similar frequencies of breakthrough lung infection as the comparable 216 groups in the previous study ( Fig 3A) , with 3 out of 8 and 2 out of 8 animals with detectable lung 217 viral load in the dose titration study, respectively ( Fig 4C) . Despite the increase in the number of 218 animals that had breakthrough infections at lower Ad26.COV2.S dose levels (6 out of 8 animals 219 that received 10 8 VP and 8 out of 8 that received 10 7 VP), the median lung viral load titers (median 220 of 10 4.8 TCID50/g at 10 8 VP, median of 10 5 TCID50/g at 10 7 VP) and IHC staining of SARS-CoV-221 2 NP in these groups (median scores 1) were lower than in the control group (median lung viral 222 load 10 6.8 TCID50/g and IHC median score 2) (Fig 4C and D) . Congruent with lung viral load and 223 IHC staining results, immunization with 10 8 , 10 9 and 10 10 VP significantly reduced histopathology 224 in the lower respiratory tract compared with mock-immunized hamsters ( Fig 5A) . Immunization 225 with 10 9 and 10 10 VP resulted in absence of any signs of lower respiratory tract histopathology in 226 4 out of 8 and 3 out of 8 hamsters, respectively. Notably, despite detectable breakthrough lung 227 13 infection in all hamsters dosed with 10 7 VP and in most hamsters immunized with 10 8 VP, median 228 lower respiratory tract histopathology scores were lower when compared with the mock 229 immunized group (Ad26.irr, Table 2 ). 230

The inflammation score of nasal tissue (rhinitis) showed no significant differences between 231 vaccinated and control groups ( Fig 5B) . Collectively, these data demonstrate that the presence of 232 low levels of neutralizing antibodies elicited by sub-optimal Ad26.COV2.S vaccine dose levels do 233 not aggravate lung disease in challenged Syrian hamsters when compared to a mock vaccine. 234

Binding and neutralizing antibodies correlate with protection. 235

To determine putative correlates of protection, binding and neutralizing antibody titers from 236 different regimens and dose levels were pooled for Ad26.COV2.S (N=56) and compared between 237 protected and unprotected animals (Fig 6) . Protection from SARS-CoV-2 infection was defined as 238 a lung viral load below 10 2 TCID/g, based on the observation that only few animals with detectable 239 viral load fall below this margin, which was likely related to variation in the available sample 240 quantity per animal (Fig 3A and B , and Fig 4C) . Protected animals dosed with Ad26.COV2.S had 241 significantly (2.3-fold) higher median binding antibody titers than unprotected animals (p<0.001, 242 two sample t-test) ( Fig 6A) . Similar results were observed for an analogous analysis of median 243 neutralizing antibody titers, which were also significantly (4-fold) increased in animals immunized 244 with Ad26.COV2.S with undetectable lung viral load compared with unprotected animals 245 (p<0.001, two sample t-test) (Fig 6B) . 246

To gain a more quantitative understanding of the relationship between immune response levels 247 and protection outcome, we built logistic regression models with Firth's correction ( Fig 6C) . 248

Hamsters were classified either as infected or protected from SARS-CoV-2, as defined above. 249

Binding antibody titers correlated significantly with protection (p=0.0004), with endpoint titers 250 above 10 3.6 appearing to be linked with protection from lung infection. Also a comparably 251 significant slope (p=0.0002) was observed with neutralizing antibody titers where titers above 32 252 appeared to be linked with protection outcome in the majority of animals. In addition, the high binding antibody levels induced by a single immunization in hamsters might 287 represent saturating levels while neutralizing antibodies could still increase after a second dose, 288 possibly reflecting extended affinity maturation. The advantage of a second homologous vaccine 289 dose for humoral SARS-CoV-2 S-specific immune responses was also observed in rabbits 290 immunized with the same Ad26-based vaccines and confirm our clinical data (Sadoff, le Gars, 291 NEJM in press). Whether a 2-dose regimen is also preferred for improved vaccine efficacy remains 292 to be seen. 293

Interestingly, a second dose of Ad26.S or Ad26.dTM.PP increased protection against lung viral 294 load after challenge compared with the low protection achieved by a single vaccination of hamsters 295 with these prototype vaccines. In contrast, a second dose of Ad26.COV2.S did not further increase 296 the already high level of efficacy established by a single dose. This is supported by our correlate 297 analysis where the probability of protection increases with a higher antibody titer, and if a certain 298 antibody titer is reached, protection probability increases only moderately. The correlation of lung 299 protection with serum binding-and neutralizing antibody levels, as observed here in the Syrian 300 hamster SARS-CoV-2-D614G challenge study, confirms our data in NHP 2 and was irrespective 301 of vaccine, dose level or regimen. 302

In addition to protection from COVID-19, vaccine-elicited immunity ideally also protects against Our study confirms that our Ad26.COV2.S vaccine candidate is highly immunogenic, and can 336 protect hamsters against challenge with a SARS-CoV-2 G614 spike variant virus. The excellent 337 potency of Ad26.COV2.S and the absence of data that it would predispose for VAERD, supports 338 its continuous evaluation in the ongoing Phase 3 clinical trials in a single and a two-dose regimen 339 (NCT04505722 and NCT04614948, respectively). 340

Vaccines 343

The Ad26-based vaccines were generated as previously 

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus 557 macaques

Ad26 vaccine protects against SARS-CoV-2 severe clinical 559 disease in hamsters

Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized 561

SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine 564 candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled 565 trial

Simulation of the clinical and pathological manifestations of 578

COVID-19) in golden Syrian hamster model: implications for 579 disease pathogenesis and transmissibility

SARS-CoV-2 viral load is associated with increased disease severity 582 and mortality

SARS-CoV-2 viral load predicts COVID-19 mortality

Immunization with SARS coronavirus vaccines leads to pulmonary 586 immunopathology on challenge with the SARS virus

Spread of SARS-CoV-2 in the Icelandic Population

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G

Increases Infectivity of the COVID-19 Virus

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and 592 transmission in vivo. Science (80-. )

Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion 594 dH69/V70. bioRxiv Prepr

Transmission of SARS-CoV-2 on mink farms between 596 humans and mink and back to humans. Science (80-. )

The circulating SARS-CoV-2 spike variant N439K maintains fitness 598 while evading antibody-mediated immunity

Spike mutation D614G alters SARS-CoV-2 fitness

Functional importance of the D614G 602 mutation in the SARS-CoV-2 spike protein

Biological challenges and technological opportunities for respiratory 605 syncytial virus vaccine development

Severe acute respiratory syndrome-associated coronavirus 607 vaccines formulated with delta inulin adjuvants provide enhanced protection while 608 ameliorating lung eosinophilic immunopathology

Effects of Toll-Like Receptor Stimulation on Eosinophilic 610 Infiltration in Lungs of BALB/c Mice Immunized with UV-Inactivated Severe Acute

Respiratory Syndrome-Related Coronavirus Vaccine

Immunization with inactivated Middle East Respiratory Syndrome 613 coronavirus vaccine leads to lung immunopathology on challenge with live virus

A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus 616

Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic 617

Proinflammatory Pulmonary Response upon Challenge

Vaccine efficacy in senescent mice challenged with recombinant SARS-619

CoV bearing epidemic and zoonotic spike variants

Severe Acute Respiratory Syndrome-Associated Coronavirus 621

Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while 622

Ameliorating Lung Eosinophilic Immunopathology

Enhanced inflammation in New Zealand white rabbits when MERS-624

CoV reinfection occurs in the absence of neutralizing antibody

Committee for Medicinal Products for Human Use. EMA Summary of opinion on 627

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, 629 double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus 630 monkeys (NHP 13-19)

Adenovectors encoding RSV-F protein induce durable and mucosal 632 immunity in macaques after two intramuscular administrations

Adenovector 26 encoded prefusion conformation stabilized RSV-F 635 protein induces long-lasting Th1-biased immunity in neonatal mice

Recombinant low-seroprevalent adenoviral vectors Ad26 638 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce 639 protective immunity against RSV infection in cotton rats

Immunogenicity 641 and protective efficacy of one-and two-dose regimens of the Ad26.COV2.S COVID-19 642 vaccine candidate in adult and aged rhesus macaques

Immunogenicity of one-and two-dose regimens of the Ad26.COV2.S 644 COVID-19 vaccine candidate in adult and aged rhesus macaques

Animal and translational models of SARS-CoV-2 infection and 646 COVID-19

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is 648 Blocked by a Clinically Proven Protease Inhibitor Article SARS-CoV-2 Cell Entry 649 Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease 650

Pathogenesis of oral type I feline 652 infectious peritonitis virus (FIPV) infection: Antibody-dependent enhancement infection 653 of cats with type I FIPV via the oral route

Recombinant Adenovirus Vaccine Vectors from Subgroups B and D

Potent 658 and short promoter for expression of heterologous genes

Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive 660

Antibody and T-Cell Responses to Multiple Filovirus Species

Evaluation of MERS-CoV Neutralizing Antibodies in Sera 662

Using Live Virus Microneutralization Assay

Virology Methods Manual -Virus isolation and 666 quantitation

Bias Reduction of Maximum Likelihood Estimates

Animals with a response at or below the 727 LLOD were put on LLOD and are shown as open symbols. Hamsters received intranasal 728 inoculation with 10 2 TCID50 SARS-CoV-2 strain BetaCoV/Munich/BavPat1/2020 4 weeks post 729 immunization (week 4). Right lung tissue was isolated 4 days after inoculation for virological 730 analysis and immunohistochemistry. c) Lung viral load was determined by TCID50 assay on Vero 731 E6 cells. The median viral load per group is indicated with a horizontal line. LLOD was calculated 732 per animal

Comparisons were performed between the Ad26.COV2.S dose level groups, with the Ad26.Irr 735 group by Mann-Whitney U-test. Statistical differences indicated by asterisks: *:p<0.05

Irr = Ad26 vector not encoding any SARS-CoV-2 antigens

LLOD = lower limit of 738 detection

TCID50/g = 50% tissue culture infective dose per gram tissue

VP = virus particles

protein; wtVNA = wild-type virus neutralization assay

No signs of VAERD in Ad26 immunized Syrian hamsters inoculated with SARS-742

CoV-2 Four days after IN inoculation with 10 2 TCID50 SARS-CoV-2 (N = 8 per group), a) lung 743 tissue was isolated and scored for presence and severity of alveolitis, alveolar damage

Sum of scores are presented as sum of LRT disease 746 parameters. b) Four days after inoculation, nose tissue was isolated and scored for severity of 747 inflammation

Symbols in red 749 denote samples from hamsters with breakthrough lung viral load (>10 2 TCID50/g). Comparisons 750 were performed between the Ad26.COV2.S dose level groups, with the Ad26

Irr = Ad26 vector not encoding any SARS-CoV-2 antigens

LRT = lower respiratory tract

VP = virus particles

Binding and neutralizing antibodies correlate with protection. Protection was 756 defined as a viral load below 10 2 TCID50/g in lung tissue, irrespective of vaccine regimen and dose 757 level (see Fig 3A and B, and Fig 4C). Syrian hamsters were immunized once, or twice

Hamsters were inoculated with 10 2 TCID50 SARS-CoV-759 2, and four days later sacrificed for virological analysis of lung tissue. Prior to virus inoculation 760 serum samples were analyzed for a) antibody binding titers and b) virus neutralizing antibodies

Median antibody responses per group is indicated with horizontal lines. Dotted lines indicate the 762

Logistic regression models using Firth's correction were built with protection outcome 763 as the dependent variable, and binding and neutralizing antibody titers from pooled regimens and 764 dose levels of Ad26.COV2.S as independent variable

LLOD = lower limit of detection

TCID50/g = 50% tissue culture infective 767 dose per gram tissue

VP = virus particles